+61.4%
AMAT vs MRNA
+945.0%
-883.7%
-48.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.3% | +13.1% | -16.4% | -3.4% |
| 7D | -11.2% | +20.6% | -31.8% | -11.3% |
| 30D | -31.9% | +27.1% | -59.0% | -32.0% |
| 3M | -32.3% | +353.4% | -385.7% | -34.1% |
| 6M | -5.4% | +446.3% | -451.7% | -14.0% |
| YTD | +44.3% | +776.2% | -731.9% | +22.9% |
| 1Y | +61.4% | +987.9% | -926.6% | +33.1% |
| All | +61.4% | +945.0% | -883.7% | +33.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling